Compare IDN & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDN | MGNX |
|---|---|---|
| Founded | 1994 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.0M | 115.8M |
| IPO Year | 2014 | 2013 |
| Metric | IDN | MGNX |
|---|---|---|
| Price | $5.51 | $2.85 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 5 |
| Target Price | ★ $7.33 | $3.40 |
| AVG Volume (30 Days) | 96.2K | ★ 1.4M |
| Earning Date | 03-19-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 220.00 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | $4,433,454.00 | ★ $149,500,000.00 |
| Revenue This Year | $12.21 | N/A |
| Revenue Next Year | $12.44 | $16.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $2.30 | $0.99 |
| 52 Week High | $7.48 | $3.50 |
| Indicator | IDN | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 61.49 | 61.95 |
| Support Level | $5.12 | $1.46 |
| Resistance Level | $5.74 | $3.50 |
| Average True Range (ATR) | 0.27 | 0.23 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 51.59 | 59.47 |
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company include solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.